00:39 , May 21, 2016 |  BC Extra  |  Company News

Avalon launches cancer play PDI Therapeutics

Avalon Ventures launched cancer immunotherapy play PDI Therapeutics Inc. (La Jolla, Calif.) as part of an expanded build-to-buy partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The newco is the first Avalon has launched since the partners...
07:00 , Jun 22, 2015 |  BioCentury  |  Finance

Build-to-buy basket

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC. The newest cohort of companies includes Adrenergics Inc.,...
07:00 , Sep 29, 2014 |  BioCentury  |  Finance

Avalon-GSK bet on familiarity, speed

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures' double launch of iron play Silarus Therapeutics Inc. and autoimmune company Thyritope Biosciences Inc. shows one more element the pharma likes about the partnership's 2013 deal to fund...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Company News

Silarus Therapeutics Inc., Thyritope Biosciences Inc., GlaxoSmithKline hematology, endocrine/metabolic, autoimmune news

Avalon Ventures and GlaxoSmithKline launched Silarus and Thyritope. Each company may receive up to $10 million in series A financing, comprising $3 million in equity investment from Avalon and up to $7 million in R&D...
03:09 , Sep 23, 2014 |  BC Extra  |  Company News

Avalon, GSK launch two newcos

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched Silarus Therapeutics Inc. (San Diego, Calif.) and Thyritope Biosciences Inc. (San Diego, Calif.). Each may receive up to $10 million in series A financing, comprising $3 million...
08:00 , Dec 19, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical and Translational...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Financial News

Sitari Pharmaceuticals completes venture financing

Sitari Pharmaceuticals, La Jolla, Calif.   Business: Autoimmune   Date completed: 11/22/13   Type: Venture financing   Raised: $10 million   Investors: GlaxoSmithKline plc; Avalon Ventures   ...
08:00 , Nov 25, 2013 |  BioCentury  |  Finance

A virtual first

A virtual first Sitari Pharmaceuticals Corp. is the first of what partners Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expect will be several virtual newcos formed over the next year under an April deal designed to...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Sitari Pharmaceuticals Corp., GlaxoSmithKline sales and marketing update

Avalon Ventures and GlaxoSmithKline launched celiac disease company Sitari, with $10 million in a series A round. The virtual newco, which is developing small molecule inhibitors of transglutaminase 2 ( TGM2; TG2), is...
02:28 , Nov 23, 2013 |  BC Extra  |  Company News

Avalon Ventures, GSK launch first newco

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched celiac disease company Sitari Pharmaceuticals Corp. (La Jolla, Calif.) with $10 million in a series A round and R&D support. The virtual newco, which is developing small...